Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912864 | 1.00 | GPR119 (0.47) | GPR119RBP4SSTR4POLBMEN1 | |
| SCHEMBL27157819 | 0.90 | RBP4 (0.47) | GPR119RBP4SSTR4POLBUSP30 | |
| SCHEMBL29912926 | 0.90 | RBP4 (0.47) | GPR119RBP4SSTR4POLBUSP30 | |
| SCHEMBL27158623 | 0.86 | RBP4 (0.54) | GPR119RBP4SSTR4POLBALOX5AP | |
| SCHEMBL30785509 | 0.86 | RBP4 (0.54) | GPR119RBP4SSTR4POLBALOX5AP | |
| SCHEMBL30785481 | 0.84 | RBP4 (0.53) | GPR119RBP4SSTR4ALOX5APFEN1 | |
| SCHEMBL30785499 | 0.84 | RBP4 (0.53) | GPR119RBP4SSTR4ALOX5APFEN1 | |
| SCHEMBL27157998 | 0.84 | RBP4 (0.53) | GPR119RBP4SSTR4ALOX5APFEN1 | |
| SCHEMBL29202348 | 0.84 | RBP4 (0.53) | GPR119RBP4SSTR4ALOX5APFEN1 | |
| SCHEMBL29913084 | 0.82 | SSTR4 (0.48) | GPR119RBP4SSTR4POLBALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117642404-A | Small molecule modulators of glucocerebrosidase activity and uses thereof | 凡况生化公司 | 2024-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | GPR119 101/4885RBP4 3791/4885SSTR4 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.